NEW YORK (GenomeWeb) – MDxHealth reported today that its fourth quarter revenues rose 68 percent percent year over year, driven largely by higher sales of its ConfirmMDx prostate cancer test.

For the three months ended Dec. 31, 2015, MDxHealth reported revenues of $5.7 million compared to $3.4 million in Q4 2014.

Sales of the ConfirmMDx test represented 86 percent of the quarter's total revenues compared to 70 percent of revenues in Q4 2014. The increase was also due in part to royalty and milestone payments from Exact Sciences.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.